http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Tsutomu Fujimura,Mitsuyuki Hotta,Takashi Kitahara,Yoshinori Takema 대한약학회 2011 Archives of Pharmacal Research Vol.34 No.6
Although there have been many reports about the relationship between force generation by skeletal muscles and aging, no study has investigated the relationship between contraction forces generated by non-muscle cells and aging. In this study, we examined that relationship using fibroblast populating collagen gels and a contraction force detecting system. Fibroblasts at passages 5 to 7 were used as the young group and those at passages 17 to 19 were used as the aged group. The contraction force induced by thrombin or lysophosphatidic acid significantly decreased with age. The expression of myosin light chain kinase (MLCK) and two types of Rho kinases (Rock-1 and Rock-2) decreased with age, but the expression of Rho A and myosin phosphatase (MPPase) did not change at all. The expression of myosin light chain 20k (MLC_20) depended on the donor fibroblasts. Fibroblasts from young or aged hairless mice showed similar age-dependent results. Taken together, our data suggest that decreased expressions of MLCK and Rho kinase are critical for loss of force generation by fibroblasts with aging, which suggests new mechanisms of functional deficiencies due to aging.
( Tomoari Kamada ),( Yoshinori Fujimura ),( Kensuke Gotoh ),( Hiroshi Imamura ),( Noriaki Manabe ),( Hiroaki Kusunoki ),( Kazuhiko Inoue ),( Akiko Shiotani ),( Jiro Hata ),( Ken Haruma ) 대한소화기학회 2013 Gut and Liver Vol.7 No.1
Background/Aims: There have been few studies on the efficacy of proton pump inhibitors and the doses required to treat dyspeptic symptoms observed in clinical practice. The aim of this study was to compare the efficacy of different doses of omeprazole and different administration methods in Helicobacter pylori-negative, dyspeptic patients. Methods: Patients with chronic upper abdominal symptoms within the previous 3 months were randomly divided into three groups: a daily, omeprazole 20 mg treatment group (OPZ20, n=61); a daily, omeprazole 10 mg treatment group (OPZ10, n=72); and an on-demand omeprazole 20 mg treatment group (ondemand, n=62). After 4 weeks of administration of the drug, symptom improvement rates were evaluated based on the Overall Global Severity score. Results: The rates of symptom improvement after 4 weeks of treatment were 65.6% (40/61) in the OPZ20 group, 47.2% (34/72) in the OPZ10 group, and 50.0% (31/62) in the on-demand group. The OPZ20 group exhibited a significantly higher improvement rate (p=0.034) than the OPZ10 group. The OPZ20 group had significant improvements in regurgitation, postprandial fullness, vomiting, and bloating compared with the OPZ10 group. Conclusions: Daily treatment with 20 mg of omeprazole was efficient in treating upper abdominal symptoms. Trial registration: ClinicalTrials.gov, number UMIN000002621. (Gut Liver 2013;7:16-22)